$9.810
+0.152 (+1.55%)At close
- High
- 10.320
- Open
- 9.550
- VWAP
- 9.89
- Vol
- 9.43K
- Mkt Cap
- 89.70M
- Low
- 9.550
- Amount
- 93.28K
- EV/EBITDA, TTM
- 1.54
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Valuation Metrics
Events Timeline
News
7.008-04NewsfilterInvestigation into Kalaris Therapeutics Shareholder Claims
7.010-16GlobenewswireBragar Eagel & Squire, P.C. Ongoing Inquiry into AlloVir, Inc. for the Benefit of Long-Term Shareholders
7.008-06GlobenewswireALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
7.003-03PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, WMPN, IPG, TURN on Behalf of Shareholders
7.002-26PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, ALVR, WMPN, AVAV on Behalf of Shareholders
ALVR FAQ — answered by Alphio AI
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.